# Argan Inc: financial statements, quarterly

AGX · NYSE · CIK 100591 · [Industrials](/sectors/industrials.md) · fiscal year ends Jan 31

Pages: [Overview](/companies/agx.md) · [Financials](/companies/agx/financials.md) · [Filings](/companies/agx/filings.md) · [Insiders](/companies/agx/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/agx/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-10-31) | Q4 FY2023 (2024-01-31) | Q1 FY2024 (2024-04-30) | Q2 FY2024 (2024-07-31) | Q3 FY2024 (2024-10-31) | Q4 FY2024 (2025-01-31) | Q1 FY2025 (2025-04-30) | Q2 FY2025 (2025-07-31) | Q3 FY2025 (2025-10-31) | Q4 FY2025 (2026-01-31) | Q1 FY2026 (2026-04-30) | Q2 FY2026 (2026-07-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [164](/filings/0001558370-24-016050.md) | [165 d](/filings/0001104659-26-035216.md) | [158](/filings/0001558370-25-008397.md) | [227](/filings/0001558370-25-011874.md) | [257](/filings/0001104659-25-118471.md) | [232 d](/filings/0001104659-26-035216.md) | [194](/filings/0001104659-26-070536.md) | [238](/filings/0001104659-26-104745.md) | [251](/filings/0001104659-25-118471.md) | [262 d](/filings/0001104659-26-035216.md) | [291](/filings/0001104659-26-070536.md) | [384](/filings/0001104659-26-104745.md) |
| Cost of revenue | $m | [145](/filings/0001558370-24-016050.md) | [141 d](/filings/0001104659-26-035216.md) | [140](/filings/0001558370-25-008397.md) | [196](/filings/0001558370-25-011874.md) | [213](/filings/0001104659-25-118471.md) | [185 d](/filings/0001104659-26-035216.md) | [157](/filings/0001104659-26-070536.md) | [193](/filings/0001104659-26-104745.md) | [204](/filings/0001104659-25-118471.md) | [196 d](/filings/0001104659-26-035216.md) | [230](/filings/0001104659-26-070536.md) | [310](/filings/0001104659-26-104745.md) |
| Gross profit | $m | [19.2](/filings/0001558370-24-016050.md) | [23.6 d](/filings/0001104659-26-035216.md) | [17.9](/filings/0001558370-25-008397.md) | [31.1](/filings/0001558370-25-011874.md) | [44.3](/filings/0001104659-25-118471.md) | [47.6 d](/filings/0001104659-26-035216.md) | [36.9](/filings/0001104659-26-070536.md) | [44.3](/filings/0001104659-26-104745.md) | [46.9](/filings/0001104659-25-118471.md) | [65.6 d](/filings/0001104659-26-035216.md) | [61.1](/filings/0001104659-26-070536.md) | [74.2](/filings/0001104659-26-104745.md) |
| Selling, general and administrative | $m | [11.4](/filings/0001558370-24-016050.md) | [11.9 d](/filings/0001104659-26-035216.md) | [11.4](/filings/0001558370-25-008397.md) | [12.4](/filings/0001558370-25-011874.md) | [14.0](/filings/0001104659-25-118471.md) | [14.9 d](/filings/0001104659-26-035216.md) | [12.5](/filings/0001104659-26-070536.md) | [14.2](/filings/0001104659-26-104745.md) | [14.3](/filings/0001104659-25-118471.md) | [17.9 d](/filings/0001104659-26-035216.md) | [15.7](/filings/0001104659-26-070536.md) | [17.4](/filings/0001104659-26-104745.md) |
| Operating income | $m | [7.9](/filings/0001558370-24-016050.md) | [11.7 d](/filings/0001104659-26-035216.md) | [6.5](/filings/0001558370-25-008397.md) | [18.7](/filings/0001558370-25-011874.md) | [30.3](/filings/0001104659-25-118471.md) | [32.7 d](/filings/0001104659-26-035216.md) | [24.3](/filings/0001104659-26-070536.md) | [30.1](/filings/0001104659-26-104745.md) | [32.6](/filings/0001104659-25-118471.md) | [47.7 d](/filings/0001104659-26-035216.md) | [45.4](/filings/0001104659-26-070536.md) | [56.8](/filings/0001104659-26-104745.md) |
| Income tax | $m | [6.1](/filings/0001558370-24-016050.md) | [5.0 d](/filings/0001104659-26-035216.md) | [3.4](/filings/0001558370-25-008397.md) | [6.1](/filings/0001558370-25-011874.md) | [9.0](/filings/0001104659-25-118471.md) | [7.3 d](/filings/0001104659-26-035216.md) | [7.2](/filings/0001104659-26-070536.md) | [0.4](/filings/0001104659-26-104745.md) | [9.0](/filings/0001104659-25-118471.md) | [6.2 d](/filings/0001104659-26-035216.md) | [7.7](/filings/0001104659-26-070536.md) | [13.6](/filings/0001104659-26-104745.md) |
| Net income | $m | [5.5](/filings/0001558370-24-016050.md) | [12.0 d](/filings/0001104659-26-035216.md) | [7.9](/filings/0001558370-25-008397.md) | [18.2](/filings/0001558370-25-011874.md) | [28.0](/filings/0001104659-25-118471.md) | [31.4 d](/filings/0001104659-26-035216.md) | [22.6](/filings/0001104659-26-070536.md) | [35.3](/filings/0001104659-26-104745.md) | [30.7](/filings/0001104659-25-118471.md) | [49.2 d](/filings/0001104659-26-035216.md) | [46.1](/filings/0001104659-26-070536.md) | [53.3](/filings/0001104659-26-104745.md) |
| Diluted EPS | $ per share | [0.40](/filings/0001558370-24-016050.md) | not reported | [0.58](/filings/0001558370-25-008397.md) | [1.31](/filings/0001558370-25-011874.md) | [2.00](/filings/0001104659-25-118471.md) | not reported | [1.60](/filings/0001104659-26-070536.md) | [2.50](/filings/0001104659-26-104745.md) | [2.17](/filings/0001104659-25-118471.md) | not reported | [3.24](/filings/0001104659-26-070536.md) | [3.76](/filings/0001104659-26-104745.md) |
| Basic EPS | $ per share | [0.41](/filings/0001558370-24-016050.md) | not reported | [0.59](/filings/0001558370-25-008397.md) | [1.36](/filings/0001558370-25-011874.md) | [2.07](/filings/0001104659-25-118471.md) | not reported | [1.65](/filings/0001104659-26-070536.md) | [2.57](/filings/0001104659-26-104745.md) | [2.22](/filings/0001104659-25-118471.md) | not reported | [3.30](/filings/0001104659-26-070536.md) | [3.80](/filings/0001104659-26-104745.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Cost of revenue: us-gaap:CostOfRevenue
- Gross profit: us-gaap:GrossProfit
- Selling, general and administrative: us-gaap:SellingGeneralAndAdministrativeExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-10-31) | FY2023 (2024-01-31) | Q1 FY2024 (2024-04-30) | Q2 FY2024 (2024-07-31) | Q3 FY2024 (2024-10-31) | FY2024 (2025-01-31) | Q1 FY2025 (2025-04-30) | Q2 FY2025 (2025-07-31) | Q3 FY2025 (2025-10-31) | FY2025 (2026-01-31) | Q1 FY2026 (2026-04-30) | Q2 FY2026 (2026-07-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [186](/filings/0001558370-23-019517.md) | [197](/filings/0001558370-25-003819.md) | [208](/filings/0001558370-24-008969.md) | [233](/filings/0001558370-24-012611.md) | [175](/filings/0001558370-24-016050.md) | [145](/filings/0001104659-26-035216.md) | [189](/filings/0001558370-25-008397.md) | [178](/filings/0001558370-25-011874.md) | [306](/filings/0001104659-25-118471.md) | [339](/filings/0001104659-26-104745.md) | [356](/filings/0001104659-26-070536.md) | [364](/filings/0001104659-26-104745.md) |
| Current assets | $m | [514](/filings/0001558370-24-016050.md) | [547](/filings/0001104659-26-035216.md) | [574](/filings/0001558370-25-008397.md) | [675](/filings/0001558370-25-011874.md) | [717](/filings/0001104659-25-118471.md) | [781](/filings/0001104659-26-035216.md) | [738](/filings/0001104659-26-070536.md) | [829](/filings/0001104659-26-104745.md) | [997](/filings/0001104659-25-118471.md) | [1,132](/filings/0001104659-26-104745.md) | [1,216](/filings/0001104659-26-070536.md) | [1,318](/filings/0001104659-26-104745.md) |
| Total assets | $m | [564](/filings/0001558370-24-016050.md) | [598](/filings/0001104659-26-035216.md) | [624](/filings/0001558370-25-008397.md) | [727](/filings/0001558370-25-011874.md) | [769](/filings/0001104659-25-118471.md) | [836](/filings/0001104659-26-035216.md) | [792](/filings/0001104659-26-070536.md) | [883](/filings/0001104659-26-104745.md) | [1,051](/filings/0001104659-25-118471.md) | [1,186](/filings/0001104659-26-104745.md) | [1,286](/filings/0001104659-26-070536.md) | [1,401](/filings/0001104659-26-104745.md) |
| Current liabilities | $m | [274](/filings/0001558370-24-016050.md) | [302](/filings/0001104659-26-035216.md) | [328](/filings/0001558370-25-008397.md) | [415](/filings/0001558370-25-011874.md) | [436](/filings/0001104659-25-118471.md) | [480](/filings/0001104659-26-035216.md) | [423](/filings/0001104659-26-070536.md) | [484](/filings/0001104659-26-104745.md) | [620](/filings/0001104659-25-118471.md) | [711](/filings/0001104659-26-104745.md) | [795](/filings/0001104659-26-070536.md) | [878](/filings/0001104659-26-104745.md) |
| Total liabilities | $m | [279](/filings/0001558370-23-019517.md) | [307](/filings/0001558370-25-003819.md) | [331](/filings/0001558370-24-008969.md) | [419](/filings/0001558370-24-012611.md) | [440](/filings/0001558370-24-016050.md) | [484](/filings/0001104659-26-035216.md) | [428](/filings/0001558370-25-008397.md) | [490](/filings/0001558370-25-011874.md) | [631](/filings/0001104659-25-118471.md) | [724](/filings/0001104659-26-104745.md) | [813](/filings/0001104659-26-070536.md) | [894](/filings/0001104659-26-104745.md) |
| Shareholders' equity | $m | [285](/filings/0001558370-23-019517.md) | [291](/filings/0001104659-26-035216.md) | [293](/filings/0001104659-25-118471.md) | [308](/filings/0001104659-25-118471.md) | [329](/filings/0001104659-25-118471.md) | [352](/filings/0001104659-26-104745.md) | [364](/filings/0001104659-26-104745.md) | [393](/filings/0001104659-26-104745.md) | [420](/filings/0001104659-25-118471.md) | [462](/filings/0001104659-26-104745.md) | [474](/filings/0001104659-26-104745.md) | [507](/filings/0001104659-26-104745.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-10-31) | Q4 FY2023 (2024-01-31) | Q1 FY2024 (2024-04-30) | Q2 FY2024 (2024-07-31) | Q3 FY2024 (2024-10-31) | Q4 FY2024 (2025-01-31) | Q1 FY2025 (2025-04-30) | Q2 FY2025 (2025-07-31) | Q3 FY2025 (2025-10-31) | Q4 FY2025 (2026-01-31) | Q1 FY2026 (2026-04-30) | Q2 FY2026 (2026-07-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [57.7 d](/filings/0001558370-24-016050.md) | [24.6 d](/filings/0001104659-26-035216.md) | [17.7](/filings/0001558370-25-008397.md) | [73.5 d](/filings/0001558370-25-011874.md) | [31.8 d](/filings/0001104659-25-118471.md) | [44.6 d](/filings/0001104659-26-035216.md) | [35.3](/filings/0001104659-26-070536.md) | [34.6 d](/filings/0001104659-26-104745.md) | [172 d](/filings/0001104659-25-118471.md) | [172 d](/filings/0001104659-26-035216.md) | [113](/filings/0001104659-26-070536.md) | [97.0 d](/filings/0001104659-26-104745.md) |
| Capital expenditure | $m | [1.1 d](/filings/0001558370-24-016050.md) | [0.6 d](/filings/0001104659-26-035216.md) | [0.3](/filings/0001558370-25-008397.md) | [2.3 d](/filings/0001558370-25-011874.md) | [2.5 d](/filings/0001104659-25-118471.md) | [1.4 d](/filings/0001104659-26-035216.md) | [0.4](/filings/0001104659-26-070536.md) | [1.7 d](/filings/0001104659-26-104745.md) | [0.6 d](/filings/0001104659-25-118471.md) | [1.2 d](/filings/0001104659-26-035216.md) | [2.4](/filings/0001104659-26-070536.md) | [5.3 d](/filings/0001104659-26-104745.md) |
| Dividends paid | $m | [4.0 d](/filings/0001558370-24-016050.md) | [4.0 d](/filings/0001104659-26-035216.md) | [4.0](/filings/0001558370-25-008397.md) | [4.0 d](/filings/0001558370-25-011874.md) | [5.2 d](/filings/0001104659-25-118471.md) | [5.0 d](/filings/0001104659-26-035216.md) | [5.1](/filings/0001104659-26-070536.md) | [5.2 d](/filings/0001104659-26-104745.md) | [7.1 d](/filings/0001104659-25-118471.md) | [7.0 d](/filings/0001104659-26-035216.md) | [7.0](/filings/0001104659-26-070536.md) | [7.0 d](/filings/0001104659-26-104745.md) |
| Share repurchases | $m | [1.7 d](/filings/0001558370-24-016050.md) | [4.0 d](/filings/0001104659-26-035216.md) | [0.2](/filings/0001558370-25-008397.md) | [0.0 d](/filings/0001558370-25-011874.md) | [0.5 d](/filings/0001104659-25-118471.md) | [0.9 d](/filings/0001104659-26-035216.md) | [6.8](/filings/0001104659-26-070536.md) | [0.2 d](/filings/0001104659-26-104745.md) | [0.0 d](/filings/0001104659-25-118471.md) | [2.8 d](/filings/0001104659-26-035216.md) | [3.0](/filings/0001104659-26-070536.md) | [6.7 d](/filings/0001104659-26-104745.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
- Dividends paid: us-gaap:PaymentsOfDividendsCommonStock
- Share repurchases: us-gaap:PaymentsForRepurchaseOfCommonStock

## Shares

| Line item | Unit | Q3 FY2022 (2022-10-31) | Q1 FY2023 (2023-04-30) | Q2 FY2023 (2023-07-31) | Q3 FY2023 (2023-10-31) | Q1 FY2024 (2024-04-30) | Q2 FY2024 (2024-07-31) | Q3 FY2024 (2024-10-31) | Q1 FY2025 (2025-04-30) | Q2 FY2025 (2025-07-31) | Q3 FY2025 (2025-10-31) | Q1 FY2026 (2026-04-30) | Q2 FY2026 (2026-07-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [13.8](/filings/0001558370-23-019517.md) | [13.5](/filings/0001558370-24-008969.md) | [13.5](/filings/0001558370-24-012611.md) | [13.6](/filings/0001558370-24-016050.md) | [13.6](/filings/0001558370-25-008397.md) | [13.9](/filings/0001558370-25-011874.md) | [14.0](/filings/0001104659-25-118471.md) | [14.1](/filings/0001104659-26-070536.md) | [14.1](/filings/0001104659-26-104745.md) | [14.2](/filings/0001104659-25-118471.md) | [14.2](/filings/0001104659-26-070536.md) | [14.2](/filings/0001104659-26-104745.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 14,029,842 at 2026-08-28, from the cover of the [10-Q filed 2026-09-02](/filings/0001104659-26-104745.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:21 ET. No prices; not investment advice.